Shaanxi BLOOM Tech Co., Ltd. is one of the most experienced manufacturers and suppliers of d chiro inositol capsule in China. Welcome to wholesale bulk high quality d chiro inositol capsule for sale here from our factory. Good service and reasonable price are available.
D Chiro Inositol Capsule is a dietary supplement designed to support metabolic and endocrine health, with its primary ingredient being D-chiro-inositol-a naturally occurring isomer of inositol. Compared to tablets, the capsule formulation offers superior absorption rates and gastrointestinal tolerability, making it particularly suitable for individuals requiring precise dosing or those who have difficulty swallowing tablets.
DCI capsules are commonly used to improve insulin resistance, polycystic ovary syndrome (PCOS), and type 2 diabetes. Its mechanism of action involves enhancing insulin signaling, promoting glucose metabolism, and regulating sex hormone balance. Studies indicate that daily supplementation with 400–1,200 mg of DCI (often combined with Myo-inositol) can improve ovulation function, reduce androgen levels, and support cardiovascular health.
The capsule shell (such as plant cellulose or gelatin) effectively protects the active components of DCI from gastric acid degradation, enhancing bioavailability. Some products also include absorption enhancers (such as piperine) to optimize efficacy. It has good safety profiles but should be avoided in combination with hypoglycemic medications to prevent hypoglycemia. It is suitable for women planning pregnancy, individuals with metabolic syndrome, and those seeking precise nutritional supplementation.
|
|
|
D Chiro Inositol Powder COA
Clinical practice framework for dose adjustment
Core Logic of Dose Adjustment: Dual Drive by Genetic Testing and Metabolic Indicators
The dose adjustment of D Chiro Inositol capsule should be based on the results of genetic testing and dynamically optimized with metabolic indicators. Genetic testing can identify polymorphisms of key genes such as CYP3A4 (metabolic enzyme), INSR (insulin receptor gene), and FSHR (follicle-stimulating hormone receptor gene), directly guiding the initial dose setting. For example, patients with the CYP3A4*1B mutation have 30% lower enzyme activity and a longer half-life of DCI, so the initial dose should be reduced from 500mg/day to 300mg/day; patients with the TT genotype of INSR rs1799817 have 40% lower sensitivity to DCI, so the dose should be increased to 800mg/day to maintain efficacy. Metabolic indicators monitoring (such as fasting blood glucose, testosterone, liver function) is used to verify the effectiveness of the dose, and is rechecked every 3 months. If the blood glucose fluctuation range exceeds the standard or there is abnormal liver function, the dose needs to be further adjusted.
Steps for Dose Adjustment in Clinical Practice
Initial Dose Setting: Genotype Stratification Strategy
CYP3A4 Genotype:
1/1 Type (Normal Enzyme Activity): 500mg/day
1B/1 Type (Enzyme Activity Reduced by 30%): 300mg/day
3/3 Type (Enzyme Activity Reduced by 70%): 150mg/day + 2g MYO (Combined用药 reduces the risk of accumulation)
INSR Genotype：
GG Type (Sensitive)： 500mg/day
TT Type (Low Sensitivity)： 800mg/day + 400IU Vitamin D (Enhances Insulin Sensitization)
FSHR Genotype：
AA Type (Poor Follicular Response)： DCI 600mg/day + MYO 2400mg/day (Optimized 40：1 ratio)
GG Type (Good Follicular Response)： DCI 500mg/day + MYO 2000mg/day (Standard Ratio)
Dose Adjustment Algorithm： Dynamic Optimization Model
Based on Metabolic Indicators：
If fasting blood glucose > 7.0 mmol/L or testosterone > 2.5 nmol/L, the dose increases by 20% (e.g., 500mg → 600mg/day);
If blood glucose < 3.9 mmol/L or ALT > 80 U/L, the dose decreases by 25% (e.g., 500mg → 375mg/day).
Based on Genetic Interactions：
Patients carrying CYP3A4*1B + INSR TT double mutations need a dose reduction of 40% (e.g., 500mg → 300mg/day), and combined with metformin 500mg/day to enhance efficacy.
Special Population Dose Adjustment
Obese PCOS Patients： For those with BMI ≥ 30 kg/m², the DCI dose needs to be corrected based on body weight (40mg/kg/day), taken in two doses. For example, a patient with a weight of 80 kg, the initial dose is 3200mg/day (1600mg in the morning and 1600mg in the evening), gradually adjusted to the effective dose.
Patients with Liver and Kidney Dysfunction：
Liver Function Abnormality (ALT > 120 U/L)： The dose is halved (e.g., 500mg → 250mg/day), and coagulation function is monitored;
Kidney Dysfunction (eGFR < 60 mL/min)： The dose is reduced by 30% (e.g., 500mg → 350mg/day), to avoid accumulation poisoning.
Key Technical Challenges and Solutions in Dose Adjustment
Cost of Testing and Accessibility
The cost of whole-genome sequencing is high. By using targeted gene panels (such as the 12-gene package related to PCOS), the cost can be reduced to $80 per case. In addition, the detection method based on fluorescence quantitative PCR has high sensitivity and low cost, suitable for clinical promotion.
Analysis of Multi-Gene Interactions
Using machine learning models to integrate multi-gene data can improve the accuracy of dose prediction. For example, the DCI dose prediction model based on the random forest algorithm has an AUC value of 0.89 in the independent validation set, which can accurately identify high-risk patients and adjust the dose.
Dynamic Dose Adjustment Mechanism
Combining genetic testing and metabolomics (such as monitoring the DCI-IPG level in urine), it is possible to achieve dynamic optimization of the dose. Studies show that adjusting the dose every 3 months can increase the rate of achieving blood sugar control by 22%. In addition, digital twin technology can build a virtual model of the patient to simulate the drug effect response under different doses, shortening the dose optimization cycle from 6 months to 2 weeks.
Future Trends： Precision Medicine Drives Industry Upgrading
Application of Synthetic Biology Technology
By modifying microbial strains through metabolic engineering, specific DCI isomers for patients with certain genotypes can be produced. For example, a "low-metabolism DCI" developed for CYP3A4*1B patients has a 40% increase in bioavailability, significantly reducing the frequency of dose adjustment.
Breakthroughs in Gene Editing Technology
The CRISPR-Cas9 technology can be used to repair gene mutations such as INSR and IRS1, fundamentally improving the efficacy of DCI. Animal experiments have shown that the sensitivity of the edited mice to DCI increased by 60%, providing a new direction for the treatment of hereditary insulin resistance.
Integration of digital twin technology
By constructing a virtual model of the patient and simulating the drug efficacy response under different doses, personalized dose adjustment can be achieved. Preclinical studies have shown that digital twin technology can shorten the DCI dose optimization cycle from 6 months to 2 weeks, significantly improving the treatment efficiency.
Intelligent Drug Delivery Technology: From Passive Administration to Active Targeting
Background of Technological Evolution: Limitations of Traditional Formulations
The traditional D-Chiro Inositol (DCI) capsules mainly adopt passive drug delivery, and have three core deficiencies:
Low bioavailability: After the ordinary capsules dissolve in the gastrointestinal tract, the DCI molecules are easily destroyed by gastric acid, and they rely on passive diffusion for absorption, resulting in a bioavailability of less than 35%.
Insufficient target tissue concentration: DCI needs to reach the target organs (such as the ovaries and liver) through the bloodstream, but the concentration of the traditional formulation in the target tissues is only 1/10 of the blood drug concentration.
Large individual variations: Differences in patient genotypes (such as the CYP3A4*1B mutation) and intestinal flora composition lead to fluctuations in drug efficacy of over 40%.
Intelligent formulation technology system: A leap from passive to active
Nanocrystal targeted delivery system
Technical principle: D Chiro Inositol capsule nanocrystals (with a particle size of less than 500nm) are prepared through high-pressure homogenization, and surface-modified with ovarian tissue-specific ligands (such as anti-mullerian hormone antibodies).
Clinical advantages:
Enhanced penetration: Nanocrystals can penetrate the intercellular spaces of follicular membrane cells, increasing the DCI concentration in the ovarian tissue by 5 times.
Sustained-release effect: Using pH-sensitive poly(lactic-co-glycolic acid) (PLGA) coating to achieve continuous release for 12 hours, reducing the fluctuation range of blood drug concentration by 60%.
Clinical trial data: In PCOS patients, this formulation increased the ovulation rate from 42% to 68%, without increasing the risk of ovarian hyperstimulation syndrome (OHSS).
Microbiota-host interaction regulation technology
Technical breakthrough:
Barrier breakthrough of the microbiota: For patients with a high proportion of Bacteroidetes (DCI-decomposing bacteria), the use of probiotics (such as Lactobacillus acidophilus LA-5) to inhibit DCI decomposition increased the intestinal DCI absorption rate by 30%.
Metabolic reprogramming: Through fecal microbiota transplantation (FMT), the intestinal microbiota structure is reconstructed, increasing the production of DCI-IPG (phosphatidylinositol glucoside) by 2 times, significantly enhancing insulin sensitivity.
Case verification: In patients with type 2 diabetes combined with PCOS, this technology reduced HbA1c from 7.8% to 6.2%, and the diversity index of the intestinal microbiota (Shannon index) increased by 1.5 times.
3D-printed personalized dosage capsules
Technical implementation:
Dose precision: Based on the patient's weight, genotype (such as the INSR TT mutation) and metabolomics data, 3D-printed intelligent capsules with a drug loading accuracy of 0.1mg are manufactured.
Release curve customization: Using a double-layer design, the outer layer rapidly releases 30% of the dose to quickly take effect, and the inner layer continuously releases the remaining dose to maintain efficacy.
Clinical benefits: In patients with the CYP3A43/3 genotype, this technology increased the rate of DCI blood drug concentration reaching the standard from 58% to 92%, and the incidence of gastrointestinal side effects decreased from 24% to 5%.
AI-driven dynamic dose adjustment system
Technical architecture:
Multimodal data fusion: Integrating continuous glucose monitoring (CGM), wearable devices (such as smart wristbands) and genetic testing data to build a patient digital twin model.
Reinforcement learning algorithm: Based on the deep Q-network (DQN) algorithm, the DCI dose is dynamically optimized every 6 hours, reducing the range of blood glucose fluctuations (SD) by 40%.
Pilot study: In 50 patients with PCOS combined with insulin resistance, this system increased treatment compliance from 65% to 92%, and the rate of achieving blood glucose control increased by 27 percentage points.
Technological synergy effect: From single treatment to system management
The integration application of intelligent formulation technologies has achieved three paradigm shifts:
Time-space expansion treatment: From "oral - systemic distribution" to "targeted - local enrichment", the drug concentration in ovarian tissue increased by 8 times.
Treatment dimension upgrade: From "single hypoglycemic effect" to "synergistic regulation of metabolic-reproductive axis", ovulation rate and insulin sensitivity improved simultaneously.
Treatment mode innovation: From "empirical medication" to "closed-loop dynamic management", the AI system increased the efficiency of dose adjustment by 10 times.
Future Prospects: Technical Bottlenecks and Breakthrough Directions
Formulation stability challenge
Nanocrystals are prone to agglomeration during longylinositol anchoring protein) need to be developed.
Individualized prediction model optimization
It is necessary to integrate epigenetic data (such as DNA methylation) to improve the accuracy of dose prediction (current AUC = 0.91).
Global industrial chain collaboration
Establish a full-chain innovative ecosystem from raw materials (China accounts for 60% of global export volume) to intelligent formulations (dominated by Europe and the United States).
adverse reaction
D Chiro Inositol Capsule (DCI) is a naturally occurring nine membered cyclic alcohol compound belonging to the inositol family. Its molecular structure is highly similar to the second messenger of insulin, inositol phosphoglycerols (IPG), and is therefore believed to improve insulin resistance and metabolic disorders by simulating the insulin signaling pathway.
Common adverse reactions and incidence rate
Gastrointestinal reactions: the most common types of adverse reactions
The incidence of nausea and vomiting is about 10% -30%, which is more common in the early stages of medication or when the dosage is too high. DCI may delay gastric emptying by activating GLP-1 receptors in the intestine, leading to food retention and feelings of fullness.
Diarrhea may be related to DCI promoting intestinal peristalsis or altering gut microbiota, with an incidence rate of approximately 5% -15%. A small number of patients (about 3% -8%) report constipation, which may be related to delayed gastric emptying or increased water absorption. Compared to a single GLP-1 receptor agonist, DCI has a slightly lower incidence of constipation, but a similar risk of diarrhea.
The incidence of abdominal distension and pain is about 5% -10%, mostly transient and related to intestinal gas accumulation or mucosal irritation.
Neurological response: Mild but requires attention
The incidence of headaches is about 5% -12%, which may be related to blood pressure fluctuations or vascular dilation. The characteristic is that it is mostly mild to moderate, and can be relieved after stopping the medication.
The incidence of dizziness and fatigue is about 3% -8%, which may be related to hypoglycemia or decreased blood pressure. The high-risk population is generally elderly patients or those with concomitant autonomic dysfunction, who have a higher risk.
Hot Tags: d chiro inositol capsule, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale